Users Online: 1757
Home Print this page Email this page
Home About us Editorial board Search Browse articles Submit article Ahead of Print Instructions Subscribe Contacts Special issues Login 
Year : 2023  |  Volume : 12  |  Issue : 1  |  Page : 158

The effect and safety of olanzapine on nausea and vomiting in children receiving moderately emetogenic chemotherapy

1 Clinical Research Development Center of Aliasghar Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Department of Pediatric, Amir Kabir Hospital, Arak University of Medical Sciences, Arak, Iran
3 Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
4 School of Medicine, Iran University of Medical Sciences, Tehran, Iran
5 Department of Basic and Laboratory Sciences, Khomein University of Medical Sciences, Khomein, Iran

Correspondence Address:
Dr. Kazem Ghaffari
Department of Basic and Laboratory Sciences, Khomein University of Medical Sciences, Khomein
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/abr.abr_356_22

Rights and Permissions

Background: In order to improve the complete recovery of nausea and vomiting, we conducted a study with the aim of preventing acute and delayed nausea and vomiting in children undergoing moderate emetogenic chemotherapy. Materials and Methods: A clinical trial study was done on 130 children received chemotherapy. Patients received olanzapine and placebo. All groups received granisetron along with dexamethasone (DEX). The severity of chemotherapy-induced nausea and vomiting (CINV) induced by chemotherapy was compared in two groups. Results: The severity of nausea on the first, second, third, and fourth days was not significantly different (P > .05) in two groups. The number of patients without vomiting was significantly different during the first 24 hours after chemotherapy between patients in the two groups (82.3% vs 64.5%; P = .016). Conclusion: This study showed that olanzapine, which acts as an inhibitor of neurotransmitters, had a favorable efficacy in controlling acute and delayed CINV. More studies with large sample size are needed to compare the effect of olanzapine with other agents including aprepitant and palonosetron in the prevention of CINV.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded49    
    Comments [Add]    

Recommend this journal